Pharmaceutical Accountability Foundation

Pharmaceutical Accountability Foundation

Striving for equal access to medicines and medical technologies

Access to medicines is a human right

At Pharmaceutical Accountability Foundation, we believe the pharmaceutical industry has to be held accountable when they limit needed access by raising prices to unsustainable levels in pursuit of unfair profits. We therefore investigate cases of pharmaceutical company abuse of market exclusivity rights to keep prices high at the expense of public health. We then work to inform the public, or take legal action if necessary.

Issues

Why is medical technology so very expensive? There are many issues in the way we currently incentivise innovation.

Solutions

There are several legal and policy solutions to stop misconduct, high prices, and limited access to medicines.

Cases

Examples of excessive pricing we have marked for investigation, or find illustrative of systemic challenges.

Recent News

Dutch Competition Authority ACM honors PAFs enforcement request and fines pharmaceutical company Leadiant with €19.5 million

Bergeijk, July 19, 2021 On September 7, 2018, the Pharmaceutical Accountability Foundation (PAF) submitted an enforcement request  for abuse of a dominant market position by the...

Moderna funnels billions and patents to tax havens

Research by SOMO and Wemos has shown that the EU has transferred an amount of more than 10 billion dollars to the Swiss bank account...

Why the VIG code of conduct fails to put health first

***original publicationdate 30-7-2020, but because of recent developments republished*** Robin Veenman (former research intern at Wemos and Pharmaceutical Accountability Foundation & master student Political Science at the...

The Pharmaceutical Accountability Foundation scores pharmaceutical companies’ behaviour regarding Covid-19 in a GCCP Scorecard. Conclusion: Big differences in adherence to human rights principles

Bergeijk, 22 January 2021 – Pharmaceutical Accountability Foundation  (PAF) publishes a GCCP scorecard of pharmaceutical companies that develop important vaccines and pharmaceuticals for the Corona...

Recent Tweets

We shouldn't be talking about #COVID19 booster shots as long as people (including HCW!) have yet to receive their first dose.

Without open access to vax technology, booster shots put further strains on limited supply.
https://msfaccess.org/msf-no-covid-19-booster-shots-anywhere-healthcare-workers-and-vulnerable-people-everywhere-have
@MSF_access

“Wealthy governments shouldn’t be prioritizing giving third doses when much of the developing world hasn’t even yet had the chance to get their first #COVID19 shots.” -- @kateelder

Healthcare workers and vulnerable people need vaccine access, now. ⬇

https://msfaccess.org/msf-no-covid-19-booster-shots-anywhere-healthcare-workers-and-vulnerable-people-everywhere-have

Load More...